

In the claims

Amend Claims 1 and 19 to read as follows

1. (Twice Amended) A buccal spray composition for transmucosal administration of a pharmacologically active compound provided that

a) where the said active compound is soluble in a pharmacologically acceptable polar solvent said composition comprises in weight % of total composition: aqueous polar solvent 30-99.69%, active compound 0.001-60%,

→ ai) where said composition in a polar solvent additionally comprises a propellant said composition comprises in total weight % of total composition: a propellant selected from the group consisting of C<sub>3-8</sub> hydrocarbon of a linear or branched configuration 2 - 10%, aqueous polar solvent 10-99%, and active compound 0.1-25%,

B<sup>2</sup> b) where said active compound is soluble in a pharmacologically acceptable non-polar solvent said composition comprises in weight % of total composition: non-polar solvent 30-99.69%, active compound 0.005-55%, and or

bi) where said composition in a non-polar solvent additionally comprises a pharmaceutically acceptable propellant said composition comprises in weight % of total composition: a propellant selected from the group consisting of C<sub>3-8</sub> hydrocarbon of a linear or branched configuration 5-80%, non-polar solvent 20-85%, active compound 0.05-50%,

wherein in a), ai), b) and bi) above, the active compound is selected from the group consisting of biologically active peptides, central nervous system active amines, sulfonyl ureas, antibiotics, antifungals, antivirals, sleep inducers, antiasthmatics, antiemetics, histamine H-2 receptor antagonists, barbiturates, prostoglandins, bronchial dilators selected from the group consisting of terbutaline, and theophylline.

B<sup>3</sup> 19. (Twice Amended) The composition of Claim 1 wherein the non-polar solvent is a mixture of saturated C<sub>8</sub> and C<sub>10</sub> triglycerides.